BridgeBio Oncology
BBOT
53 hedge funds and large institutions have $756M invested in BridgeBio Oncology in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
26% more funds holding
Funds holding: 42 → 53 (+11)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more capital invested
Capital invested by funds: $658M → $756M (+$98.6M)
1.16% more ownership
Funds ownership: 71.74% → 72.9% (+1.2%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.12M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$5.08M |
| 3 |
CCM
Catalio Capital Management
New York
|
+$4.98M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.79M |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$5.3M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$3.33M |
| 3 |
Millennium Management
New York
|
-$1.55M |
| 4 |
SC
Stempoint Capital
New York
|
-$1.21M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $50K | +$32.2K | +2,661 | +200% |
|
52
Rockefeller Capital Management
New York
| $8.76K | +$8.48K | +700 | New |
|
53
Wells Fargo
San Francisco,
California
| $3.76K | +$3.63K | +300 | New |
|
|
SCM
54
Silverarc Capital Management
Boston,
Massachusetts
| – | -$5.3M | -457,414 | Closed |
|
|
CUAMC
55
China Universal Asset Management Company
Shanghai,
China
| – | -$57.9K | -5,000 | Closed |
|
|
FIA
56
FNY Investment Advisers
New York
| – | -$1K | -100 | Closed |
|
BBOT Hedge Fund Activity: Q4 2025 in Review
53 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q4 2025, worth a combined $756M — up 15% from $658M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new BBOT positions and 4 closed out — a net gain of 11 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Armistice Capital, adding an estimated $7.12M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $5.3M sold.
- 53 institutional investors held BridgeBio Oncology (BBOT) as of Q4 2025, up from 42 in Q3 2025.
- Funds reported $756M of BridgeBio Oncology stock for Q4 2025, up 15% quarter-over-quarter.
- 15 funds opened new BridgeBio Oncology positions in Q4 2025 and 4 closed out, a net change of +11 holders.
- The largest BridgeBio Oncology buyer in Q4 2025 was Armistice Capital, an estimated $7.12M added.
- The largest BridgeBio Oncology seller in Q4 2025 was Silverarc Capital Management, an estimated $5.3M sold.
Based on aggregated 13F filings for Q4 2025.